Trump Administration Imposes Temporary Import Duties Following Supreme Court Ruling
Despite recent legal challenges to the Trump administration’s sweeping tariffs, a Section 232 investigation is ongoing for imports of medical...
The Centers for Medicare & Medicaid Services (CMS) is expanding Medicare coverage for genetic testing through the MolDX program administered by Palmetto GBA.
CMS announced two new local coverage determinations (LCDs) to cover diagnostic tests used to evaluate and manage care for patients suspected of having hereditary transthyretin amyloidosis:
- Genetic Testing for Heritable Thoracic Aortic Disease (L39933)
- Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (L39935)
The LCDs will take effect Aug. 17 in 23 states.
Source:
https://www.cap.org/advocacy/latest-news-and-practice-data/july-8-2025
UHC Routine Testing Management Policies to Be Implemented in Three More States in April
UnitedHealthcare (UHC) is now implementing new Routine Testing Management Policies for laboratory services, tests, and procedures in North Carolina,...
TELCOR Sponsors Sonic Medical Leadership Summit 2026
Lincoln, Nebraska – February 24, 2026 – TELCOR Inc is proud to be an Ultimate Diamond Partner of the Sonic Healthcare USA Medical Leadership Summit, ...